β-Adrenergic Receptor Inhibitor and Oncolytic Herpesvirus Combination Therapy Shows Enhanced Antitumoral and Antiangiogenic Effects on Colorectal Cancer

Hu, Jiali; Chen, Cuiyu; Lu, Ruitao; Wang, Yang; Hu, Qian-Nan; Li, Wanting; Wang, Shiyu; Ouyang, Jing; Yi, Hanying; Zhang, Wei; Chen, Ling; Huang, Weihua; Luo, Jiayou; McLeod, Howard L.; Xu, Ran; He, Yijing

doi:10.3389/fphar.2021.735278

Cited by 6 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, propranolol and T1012 combined therapy promoted vascular endothelial growth factor secretion inhibition. However, this combined treatment does not promote viral replication compared to that of cetuximab in an animal study (Hu et al, 2021a).…”

Section: Colorectal Cancermentioning

confidence: 82%

Oncolytic Viruses: Immunotherapy Drugs for Gastrointestinal Malignant Tumors

Oduro

Guo

et al. 2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Oncolytic virus therapy has advanced rapidly in recent years. Natural or transgenic viruses can target tumor cells and inhibit tumor growth and metastasis in various ways without interfering with normal cell and tissue function. Oncolytic viruses have a high level of specificity and are relatively safe. Malignant tumors in the digestive system continue to have a high incidence and mortality rate. Although existing treatment methods have achieved some curative effects, they still require further improvement due to side effects and a lack of specificity. Many studies have shown that oncolytic viruses can kill various tumor cells, including malignant tumors in the digestive system. This review discusses how oncolytic virus therapy improves malignant tumors in the digestive system from the point-of-view of basic and clinical studies. Also, the oncolytic virus anti-tumor mechanisms underpinning the therapeutic potential of oncolytic viruses are expounded. In all, we argue that oncolytic viruses might eventually provide therapeutic solutions to malignant tumors in the digestive system.

show abstract

Section: Colorectal Cancermentioning

confidence: 82%

Oncolytic Viruses: Immunotherapy Drugs for Gastrointestinal Malignant Tumors

Oduro

Guo

et al. 2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

“…OVs also stimulate the production of CXCL9 and CXCL10, providing critical signals for T cell trafficking. Furthermore, OVs can induce degradation of the tumor stroma, breaking down physical barriers to T cell infiltration [ 32 ]. However, using OVs alone may not sustain long-term immune responses and may lead to immune resistance.…”

Section: Resultsmentioning

confidence: 99%

PD-1/PD-L1 inhibitors for early and middle stage microsatellite high-instability and stable colorectal cancer: a review

Wu,

Deng,

Xue

et al. 2024

Int J Colorectal Dis

View full text Add to dashboard Cite

Background Programmed cell death receptor 1 (PD-1) and programmed cell death ligand 1 (PD-L1) are important immune checkpoint molecules that contribute to tumor immune evasion. However, the main treatment modalities for patients with early and intermediate stage colorectal cancer (CRC) are surgery, and the role of PD-1/PD-L1 inhibitors in these patients is not yet clear. Therefore, this study aims to review the treatment progress of PD-1/PD-L1 inhibitors for early- and intermediate-stage microsatellite high-instability (MSI-H) and stable (MSS) colorectal cancer, in order to provide more options for patients with early- and intermediate-stage colorectal cancer. Materials and methods A scoping review of clinical trial registries (Clinicaltrials.gov and EU clinical trial registers) and PubMed/Medline database of trials on PD-1/PD-L1 Inhibitors for early and middle-stage MSI-H and MSS CRC was done up to March 2024. Results A total of 19 trials related to early to mid-stage MSH-I or MSS CRC were included. Among them, 6 trials are in recruiting status, 3 trials are in active, not recruiting status, 3 trials are completed, 1 trial is terminated, and 1 trial is unknown. Of these, 9 trials involve MSI-H type CRC, and 10 trials involve MSS type CRC. Preclinical phase I/II trials are predominant, with only 3 clinical phase III trials. In trials related to MSI-H type CRC, 4 studies involve PD-1/PD-L1 inhibitors combined with neoadjuvant therapy, and 5 studies involve combination therapy. In trials related to MSS type CRC, 3 studies involve PD-1/PD-L1 inhibitors combined with targeted therapy, 2 studies involve PD-1/PD-L1 inhibitors combined with chemotherapy, 1 study involves PD-1/PD-L1 inhibitor combined immunotherapy, 1 study involves PD-1/PD-L1 inhibitors combined with bacterial therapy, and 3 studies involve PD-1/PD-L1 inhibitors combined with comprehensive therapy. As for primary outcome measures, 4 trials select pathological complete response rates, 3 trials select progression-free survival rate, 3 trials select objective response rate, 3 trials select overall survival rate, 4 trials select disease-free survival rate, 1 trial selects clinical complete response rate, and 1 trial selects percentage of participants with a dose-limiting toxicity. Conclusion For early- and middle-stage MSI-H and MSS CRC, PD-1/PD-L1 inhibitors have shown some therapeutic efficacy, as evidenced by phase I/II studies. However, contemporary trial designs exhibit heterogeneity, with relatively few inclusion criteria, the use of various drug combinations and regimens, and significant variations in reported endpoints. Nevertheless, more double-arm, multicenter, randomized controlled trials are still needed to confirm the efficacy of immunotherapy.

show abstract

“…Besides direct lysis of cancer cells, OVs attack tumor vasculature and eventually lead to thrombosis and vascular atrophy, leading to ischemia and hypoxia in cancer cells and reducing subsequent viral spread within tumor tissue. 116 The strategy of lyssavirus attack on the tumor vascular system is to target vascular endothelial cells within the tumor while selectively enhancing tumor vascular permeability. 117 An experimental study showed that oncolytic adenovirus can infect, replicate, and expand in tumor-associated endothelial cells, causing inhibition of tumor angiogenesis.…”

Section: Use Of Ov and Ifn Tampering In The Treatment Of Crcmentioning

confidence: 99%